Clinical Trials Browser

Phase 2 × Interventional × Fanconi Anemia, Complementation Group D1 × Clear all

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT04038502 2025-08-20

COBRA

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Phase 2 Recruiting

23 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 2 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

Phase 2 Completed

54 enrolled 17 charts

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Phase 2 Completed

97 enrolled 22 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

Phase 2 Completed

58 enrolled 13 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00677079 2013-10-01

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

12 enrolled

Classical hematology

Fanconi Anemia, Complementation Group D1

NCT01772979 2013-01-21

MITO15

Phase 2 Unknown

100 enrolled

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Clinical Trials

Olaparib In Metastatic Breast Cancer

COBRA

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

ICEBERG 1

ICEBERG 3

ICEBERG 2

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MITO15